RxDoctor Payments DataLook up a doctor →

Ahmed Malik, MD

Nephrology · Milwaukee, WINPI 1679548135

Payments from drug & device makers

$22,163in general payments, 2019–2025

Across 623 payments — averaging $35.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$8K
  • Sanofi$4K
  • Amgen$2K
  • AstraZeneca$1K
  • Vifor Pharma, Inc.$947
  • Otsuka America Pharmaceutical, Inc.$814
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$3,40023%
  • Food & beverage$10,87374%
  • Education$3512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,163 in reported general payments places this provider in the 85th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$209,053
Medicare patients
292
Services billed
1,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl19$70,050
VelphoroSucroferric Oxyhydroxide21$69,737
VeltassaPatiromer Calcium Sorbitex32$35,955
AuryxiaFerric Citrate12$29,993
FarxigaDapagliflozin Propanediol23$25,503
LokelmaSodium Zirconium Cyclosilicate18$23,615
KerendiaFinerenone15$21,642
Sevelamer Carbonate89$18,633
Potassium Citrate ErPotassium Citrate54$6,475
Midodrine Hcl46$4,079
Pentoxifylline89$3,388
Furosemide284$1,888
Hydralazine Hcl84$1,465
Calcitriol86$1,407
Calcium Acetate29$1,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$320$69,73721 claims
AstraZenecaFarxiga, Lokelma$1,362$49,11841 claims
Akebia Therapeutics IncAuryxia$7,743$29,99312 claims
BayerKerendia$191$21,64215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 173 nephrology providers in Wisconsin.

Other nephrology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →